Sympathoadrenergic mechanisms in functional regulation and development of cardiac hypertrophy and failure: Findings from genetically engineered mice

Cardiovascular Research

Volumn 50, Issue 3, 2001, Pages 443-453

  Du, Xiao Jun ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Autonomic nervous system; Cardiomyopathy; Heart failure; Hypertrophy; Receptors; Signal transduction

Indexed keywords

ADENYLATE CYCLASE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR KINASE 1; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; CALSEQUESTRIN; CATECHOLAMINE; CYCLIC AMP; DOPAMINE BETA MONOOXYGENASE; G PROTEIN COUPLED RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; MYOSIN HEAVY CHAIN; NERVE GROWTH FACTOR; NORADRENALIN; PHOSPHOTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN KINASE C; RECEPTOR SUBTYPE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; AUTONOMIC NERVOUS SYSTEM; CARDIOMYOPATHY; CATECHOLAMINE SYNTHESIS; CHRONOTROPISM; CROSS BREEDING; ENZYME ACTIVITY; GENE DISRUPTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC COMPLEMENTATION; GENETIC ENGINEERING; HEART FAILURE; HEART HYPERTROPHY; INOTROPISM; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; RECEPTOR DENSITY; REVIEW; SYMPATHETIC TONE;

ADRENERGIC FIBERS; ANIMALS; CARDIOMEGALY; HEART FAILURE, CONGESTIVE; MICE; MICE, TRANSGENIC; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 0035007170     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00244-9     Document Type: Review

References (92)

1. Brodde O.E., Michel M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol. Rev. 51:1999;651-689.
2. Lefkowitz R.J. G-protein-coupled receptor kinases. Annu. Rev. Biochem. 67:1998;653-692.
3. 2-adrenergic signal transduction. Circ. Res. 85:1999;1092-1100.
4. Hajjar R.J., Muller F.U., Schmitz W., et al. Molecular aspects of adrenergic signal transduction in cardiac failure. J. Mol. Med. 76:1998;747-755.
5. Dorn G.W.I.I., Brown J.H. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc. Med. 9:1999;26-34.
6. Esler M., Kaye D., Lambert G., Esler D., Jennings G. Adrenergic nervous system in heart failure. Am. J. Cardiol. 80:(Suppl):1997;7L-14L.
7. Bristow M.R. Mechanism of action of β-blocking agents in heart failure. Am. J. Cardiol. 80:(Suppl):1997;26L-40L.
8. 1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. USA. 96:1999;7059-7064.
9. 1-adrenergic receptor gene: Developmental and cardiovascular effects. Proc. Natl. Acad. Sci. USA. 93:1996;7375-7380.
10. 2-adrenergic receptor. Science. 264:1994;582-586.
11. 2-adrenergic receptor overexpression in mouse hearts: Critical role for expression level. Circulation. 101:2000;1707-1714.
12. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc. Natl. Acad. Sci. USA. 93:1996;10483-10488.
13. 2 adrenergic receptor gene. J. Biol. Chem. 274:1999;16694-16700.
14. 3-adrenergic receptors (abstract). Circulation. 102:(Suppl):2000;II-276.
15. 3-adrenergic receptor gene. J. Biol. Chem. 270:1995;29483-29492.
16. 3-adrenoceptor in the regulation of body composition. J. Clin. Invest. 100:1997;1098-1106.
17. 2-adrenergic receptors. J. Biol. Chem. 274:1999;16701-16708.
18. 1A-adrenergic receptor overexpression induces enhanced cardiac contractility but no hypertrophy. Submitted.
19. 1B-adrenergic receptors. J. Biol. Chem. 272:1997;21253-21259.
20. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc. Natl. Acad. Sci. USA. 91:1994;10109-10113.
21. 1b-adrenergic receptor. Proc. Natl. Acad. Sci. USA. 94:1997;11589-11594.
22. Gaudin C., Ishikawa Y., Wight D.C., et al. Overexpression of Gsα protein in the hearts of transgenic mice. J. Clin. Invest. 95:1995;1676-1683.
23. Redfern C.H., Degtyarev M.Y., Kwa A.T., et al. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc. Nat. Acad. Sci. USA. 97:2000;4826-4831.
24. Rodolph U., Spicher K., Birnbaumer L. Adenylyl cyclase inhibition and altered G protein subunit expression and ADP-ribosylation patterns in tissues and cells from Gi2α-/- mice. Proc. Natl. Acad. Sci. USA. 93:1996;3209-3214.
25. Jain M., Lim C.C., Nagata K., et al. Targeted inactivation of Gαi does not alter cardiac function or β-adrenergic sensitivity. Am. J. Physiol. 280:2001;H569-H575.
26. 2 suppressed by inducible antisense RNA. Dev. Genet. 14:1993;266-273.
27. D'Angelo D.D., Sakata Y., Lorenz J.N., et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA. 91:1997;8121-8126.
28. Mende U., Kagen A., Cohen A., Aramburu J., Schoen F.J., Neer E.J. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl. Acad. Sci. USA. 95:1998;13893-13898.
29. Akhter S.A., Luttrell L.M., Rockman H.A., et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 280:1998;574-577.
30. Rogers J.H., Tamirisa P., Kovacs A., et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104:1999;567-576.
31. Gao M.H., Lai N.C., Roth D.M., et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 99:1999;1618-1622.
32. Tepe N.M., Liggett S.B. Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of β-adrenergic receptor dysfunction in the Gαq overexpressing mouse. FEBS Lett. 458:1999;236-240.
33. 2+-stimulated adenylyl cyclase. Circ. Res. 86:2000;795-801.
34. Bowman J.C., Steinberg S.F., Jiang T., Geenen D.L., Fishman G.I., Buttrick P.M. Expression of protein kinase C-β in the heart causes hypertrophy in adult mice and sudden death in neonates. J. Clin. Invest. 100:1997;2189-2195.
35. 2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. USA. 94:1997;9320-9325.
36. Koch W.J., Rockman H.A., Samama P., et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science. 268:1995;1350-1353.
37. Jaber M., Koch W.J., Rockman H., et al. Essential role of β-adrenergic receptor kinase 1 in cardiac development and function. Proc. Natl. Acad. Sci. USA. 93:1996;12974-12979.
38. Conner D.A., Mathier M.A., Mortensen R.M., et al. β-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to β-adrenergic stimulation. Circ. Res. 81:1997;1021-1026.
39. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.T. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science. 286:1999;2495-2498.
40. Hassankhani A., Steinhelper M., Soonpaa M.H., et al. Overexpression of NGF within the heart of transgenic mice causes hyperinnervation, cardiac enlargement, and hyperplasia of ectopic cells. Dev. Biol. 169:1995;309-321.
41. Zhou Q.Y., Quaife C.J., Palmiter R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature. 374:1995;640-643.
42. Thomas S.A., Matsumoto A.M., Palmiter R.D. Noradrenaline is essential for mouse fetal development. Nature. 374:1995;643-646.
43. Cases O., Seif I., Grimsby J., et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science. 268:1995;1763-1766.
44. 2a-adrenergic receptor via 'hit and run' gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc. Natl. Acad. Sci. USA. 94:1997;9950-9955.
45. 2A-adrenergic receptor subtype. Science. 273:1996;801-803.
46. 2-adrenergic receptor subtypes b and c. Science. 273:1996;803-805.
47. 2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 402:1999;181-183.
48. 1-adrenergic receptor in transgenic mice. J. Mol. Cell Cardiol. 32:2000;817-830.
49. 2-adrenergic receptors. Am. J. Physiol. 271:1996;H630-H636.
50. 2-adrenoceptor. J. Biol. Chem. 275:2000;21773-21779.
51. 2-adrenoceptors. Br. J. Pharmacol. 129:2000;1285-1288.
52. White D.C., Hata J.A., Shah A.S., Glower D.D., Lefkowitz R.J., Koch W.J. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc. Natl. Acad. Sci. USA. 97:2000;5428-5433.
53. 2-adrenergic receptors in the heart. Cardiovasc. Res. 48:2000;448-454.
54. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. 102:1998;1532-1539.
55. 2-adrenergic receptor determine exercise capacity in patients with heart failure. Circulation. 86:2000;834-840.
56. 1B-adrenergic receptors after pressure overload in mouse heart. Am. J. Physiol. 279:2000;H1079-H1086.
57. Eckhart A.D., Duncan S.J., Penn R.B., Benovic J.L., Lefkowitz R.J., Koch W.J. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ. Res. 86:2000;43-50.
58. 1BAR regulates βAR activity via molecular crosstalk. J. Mol. Cell Cardiol. 30:1998;1827-1839.
59. 1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am. J. Physiol. 275:1998;H1338-H1350.
60. Winstel R., Freund S., Krasel C., Hoppe E., Lohse M.J. Protein kinase cross-talk: membrane targeting of the β-adrenergic receptor kinase by protein kinase C. Proc. Natl. Acad. Sci. USA. 93:1996;2105-2109.
61. 1B adrenergic receptor chronically treated with phenylephrine (abstract). Circulation. 98:(Suppl I):1998;I-69.
62. Iwase M., Bishop S.P., Uechi M., et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsα overexpression. Circ Res. 78:1996;517-524.
63. Geng Y.J., Ishikawa Y., Vatner D.E., et al. Apoptosis of cardiac myocytes in Gsα transgenic mice. Circ. Res. 84:1999;34-42.
64. Uechi M., Asai K., Osaka M., et al. Depressed heart rate variability and arterial baroreflex in conscious transgenic mice with overexpression of cardiac Gsα Circ. Res. 82:1998;416-423.
65. Asai K., Yang G.P., Geng Y.J., et al. β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse. J. Clin. Invest. 104:1999;551-558.
66. Adams J.W., Sakata Y., Davis M.G., et al. Enhanced Gαq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. USA. 95:1998;10140-10145.
67. Sakata Y., Hoit B.D., Liggett S.B., Walsh R.A., Dorn G.W.I.I. Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation. 97:1998;1488-1495.
68. Nakaoka H., Perez D.M., Baek K.J., et al. Gh, a GTP-binding protein with transglutaminase activity and receptor signaling function. Science. 264:1994;1593-1596.
69. Small K., Feng J.F., Lorenz J., et al. Cardiac specific overexpression of transglutaminase II (Gh) results in a unique hypertrophy phenotype independent of phospholipase C activation. J. Biol. Chem. 274:1999;21291-21296.
70. Rockman H.A., Choi D.J., Akhter S.A., et al. Control of myocardial contractile function by the level of β-adrenergic receptor kinase 1 in gene-targeted mice. J. Biol. Chem. 273:1998;18180-18184.
71. Akhter S.A., Eckhart A.D., Rockman H.A., Shortwell K., Lefkowitz R.J., Koch W.J. In vivo inhibition of elevated myocardial β-adrenergic receptor kinase activity in hybrid transgenic mice restores normal β-adrenergic signaling and function. Circulation. 100:1999;648-653.
72. Manning B.S., Shotwell K., Mao L., Rockman H.A., Koch W.J. Physiological induction of a β-adrenergic receptor kinase inhibitor transgene preserves β-adrenergic responsiveness in pressure-overloaded cardiac hypertrophy. Circulation. 102:2000;2751-2757.
73. 2-adrenergic receptors on cardiac myocyte apoptosis. Role of a pertussis toxin-sensitive G-protein. Circulation. 100:1999;2210-2212.
74. 2-adrenoceptors. J. Auton. Nerv. Syst. 79:2000;108-116.
75. 1-adrenoceptors. Am. J. Physiol. 271:1996;H1465-H1472.
76. 2-adrenergic receptor and expression of a β-adrenergic receptor kinase-1 (βARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ. Res. 85:1999;1077-1084.
77. Health B.M., Xia J., Dong E., et al. Overexpression of nerve growth factor in the heart alters ion channel activity and β-adrenergic signalling in an adult transgenic mouse. J. Physiol. 512:1998;779-791.
78. Dong E., Brood A., Federoff H.J., Liang C.S. Alteration in myocardial β-adrenoceptor subtypes and signal transduction pathway in nerve growth factor overexpressing transgenic mice. J. Am. Coll. Cardiol. 32:1998;177A.
79. Cho M.C., Rao M., Koch W.J., Thomas S.A., Palmiter R.D., Rockman H.A. Enhanced contractility and decreased β-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine. Circulation. 99:1999;2702-2707.
80. 2A-adrenergic receptor knockout mice. Mol. Pharmacol. 56:1999;154-161.
81. 2A-adrenergic receptor subtype. Hypertension. 34:1999;403-407.
82. Arber S., hunter J.J., Ross J. Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 88:1997;393-403.
83. Fentzke R.C., Korcarz C.E., Lang R.M., Lin H., Leiden J.M. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J. Clin. Invest. 101:1998;2415-2426.
84. Vikstrom K.L., Bohlmeyer T., Factor S.M., Leinwand L.A. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ. Res. 82:1998;773-778.
85. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
86. Rockman H.A., Chien K.R., Choi D.J., et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. USA. 95:1998;7000-7005.
87. 2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc. Natl. Acad. Sci. USA. 96:1999;6400-6405.
88. Roth D.M., Gao M.H., Lan C., et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation. 99:1999;3099-3102.
89. Harding V.B., Rapacciuolo A., Mao L., Lefkowitz R.J., Rockman H.A. βARK1 inhibition improves survival and cardiac function in a mouse model of severe cardiomyopathy (abstract). Circulation. 100:(Suppl I):1999;I552.
90. 2 adrenergic receptor accelerates heart failure in hypertrophic cardiomyopathy mice (abstract). Circulation. 100:(Suppl I):1999;I-493.
91. 2-Adrenergic receptor overexpression exacerbates development of heart failure following aortic stenosis. Circulation. 101:2000;71-77.
92. 2-Adrenergic receptor overexpression driven by an α-MHC promoter is downregulated in hypertrophied and failing myocardium. Cardiovasc. Res. 47:2000;133-141.